PEOPLE - Monogram Biosciences makes appointment:
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has promoted Gordon Parry to the position of vice-president, R&D, oncology. Dr Parry will have responsibility for Monogram's oncology programmes, including the further development of the San Francisco, California firm's VeraTag technology and the first product based on that platform - the HERMark breast cancer assay. Dr Parry joined Monogram in 2007; before that, he worked for 12 years at Berlex Biosciences where he was the department head of the cancer research department. Previously, he held a variety of research positions in academia, including ten years at the University of California's Lawrence Berkeley Laboratory. He is also an advisory council member for the California Breast Cancer Research Program.